From the AJMC Journal 02/27/2025: “At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline.”
Per the article by Rose McNulty—
At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline.
Patients with compensated metabolic dysfunction–associated steatohepatitis (MASH) cirrhosis who received resmetirom (Rezdiffra; Madrigal Pharmaceuticals) experienced reductions in liver stiffness in the phase 3 MAESTRO-NAFLD-1 trial (NCT04197479), according to 2-year results announced in a press release.
In the MAESTRO-NAFLD-1 trial, liver stiffness—a surrogate for fibrosis—was measured by vibration-controlled transient elastography (VCTE). There were 101 participants with VTCE results after 2 years of treatment in the open-label active treatment arm of patients with compensated MASH cirrhosis (stage F4c). At baseline, mean liver stiffness was 25 kPa.
At 2 years, participants in the compensated MASH cirrhosis treatment arm experienced a statistically significant reduction in liver stiffness from baseline.
At 2 years, participants in the compensated MASH cirrhosis treatment arm experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline. At 1 year, there was a 6.1 kPa reduction in liver stiffness from baseline. Notably, these results show the largest reduction in liver stiffness reported in a population of patients with F4c MASH to date.
“These data demonstrating patients with compensated MASH cirrhosis achieved marked reductions in VCTE are highly encouraging,” Mazen Noureddin, MD, MHSc, professor of medicine and director of Houston Research Institute and chief scientific officer of Summit Clinical Research, said in a statement. “We use the ‘Baveno rule of 5 kPa’ to stratify risk of liver-related events in patients with MASH, so a mean 6.7 kPa reduction suggests that many patients are moving into a lower risk category. The results are particularly meaningful in light of recently published, multicenter, longitudinal studies demonstrating VCTE is a strong predictor of clinical outcomes and may be more predictive of clinical outcomes than fibrosis stage assessed by liver biopsy.”